Sanjeev Jain, PhD
Allergy & Immunology · Longview, WANPI 1710973839
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 1,218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations.
Across 1,218 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- GSK$4K
- CSL Behring$2K
- Grifols USA, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Pfizer$1K
- plus $11K from 40 others
Across 65 payments — averaging $5636.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$229K
- Pfizer$88K
- Aimmune Therapeutics, Inc.$33K
- Biocryst Pharmaceuticals, Inc.$14K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Astrazeneca UK Limited$87
What the payments were for
- Consulting fees$1801%
- Food & beverage$24,77298%
- Education$2851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,237 in reported general payments places this provider in the 85th percentile of 81 allergy & immunology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 18 | $914,837 |
| HaegardaC1 Esterase Inhibitor | 21 | $789,226 |
| XolairOmalizumab | 190 | $669,332 |
| Dupixent SyringeDupilumab | 54 | $205,124 |
| TezspireTezepelumab-Ekko | 44 | $188,799 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 225 | $174,638 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 13 | $115,606 |
| FasenraBenralizumab | 19 | $111,783 |
| Dupixent PenDupilumab | 28 | $99,445 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $72,405 |
| NucalaMepolizumab | 17 | $62,048 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $33,803 |
| Cromolyn Sodium | 96 | $30,504 |
| Spiriva RespimatTiotropium Bromide | 56 | $29,070 |
| Epinephrine | 122 | $28,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Cuvitru | $1,365 | $987,24229 claims |
| CSL BehringHaegarda | $1,621 | $789,22621 claims |
| Genentech, Inc.Xolair | $21 | $669,332190 claims |
| AstraZenecaTezspire, Fasenra, Breztri Aerosphere, Symbicort, Airsupra | $4,578 | $355,197187 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta | $4,479 | $247,910257 claims |
| Bio Products Laboratory USA, Inc.Gammaplex | $160 | $115,60613 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $34 | $30,50496 claims |
| Boehringer IngelheimSpiriva Respimat | $527 | $29,07056 claims |
| MerckDulera | $94 | $17,11745 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $264 | $7,02015 claims |
| Covis Pharma GmbHAlvesco | $78 | $3,04011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 81 allergy & immunology providers in Washington.
Other allergy & immunology in Longview
- Taiil SongLakewood$192K
- Frank VirantSeattle$107K
- Richard GowerSpokane$104K
- Leonard AltmanSeattle$81K
- Daniel PetroniSeattle$68K
- David McGarrySpokane Valley$66K
- Rahool DaveSeattle$42K
- David ElkayamBellingham$39K
- Matthew AltmanSeattle$37K
- Arthur VeghTacoma$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.